Tilapertin (INN), also known as AMG-747,[1] is a investigational drug which was being evaluated as an antipsychotic.[2]

Mechanism of action

Tilapertin appears to act via the blocking of the type 1 glycine transporter,[3] making it a glycine re-uptake inhibitor.

History

Two studies have been made in order to determine the safety of tilapertin and its potential as an add-on to anti-psychotic therapy in people with schizophrenia. These studies were later halted due to a case of Stevens–Johnson syndrome in one of the participants.[3]

See also

References

  1. ^ "Tilapertin". PubChem. U.S. National Library of Medicine. Retrieved 2024-08-16.
  2. ^ World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN): Proposed INN: List 110" (PDF). WHO Drug Information. 27 (4). World Health Organization.
  3. ^ a b Dunayevich E, Buchanan RW, Chen CY, Yang J, Nilsen J, Dietrich JM, et al. (April 2017). "Efficacy and safety of the glycine transporter type-1 inhibitor AMG 747 for the treatment of negative symptoms associated with schizophrenia". Schizophrenia Research. 182: 90–97. doi:10.1016/j.schres.2016.10.027. PMID 27789188.
Allikas: https://en.wikipedia.org/wiki/Tilapertin
No tags for this post.